April 14, 2025  India’s pharmaceutical industry, a global powerhouse, sends...

How long before digital Unicorns like Ola, Swiggy, Pharmeasy, and many others realize the humongous opportunity of delivering health care at the doorstep? Imagine an app like Ola, where instead of entering where you want to go, you enter the nature of your medical need/emergency and search and find a range of hospitals/doctors/paramedics who can act as the first responders and reach your home in an ambulance or a motorbike with an HCP as a pillion rider with all necessary equipment from the thermometer to defibrillator depending on the nature of the medical care needed and triage and route you/your loved ones to the nearest hospital with an indicative cost of treatment in partnership with health insurance companies?

Indian healthcare is sometimes an enigma: on one hand...

The pill is now a commodity that many of these companies provide at heavy discounts, making money off everything ‘beyond the pill’. Investors are betting heavily on the potential of technological innovation to transform the way healthcare is delivered. The Economic Times reported that in 2021, India recorded investments of $77 billion across 1,266 deals including 164 large deals worth $58 billion. While the money reduced in 2022, the reason wasn’t a lack of faith in this business model. Meanwhile, the pharmaceuticals industry that is most affected by this quiet but rapid change, is grappling with its entrenched culture. Its current business is so profitable that everything else pales in comparison. ‘Build, measure, learn, build again’ – a mantra of the health tech industry is alien to pharma that doesn’t learn, build or measure after launching a product. Pharma also thinks of its customers as doctors alone and does precious little to connect with patients, or caregivers. People who are not sick do not feature on their radar at all. These are cultural values that keep pharma focused on the pill and discourage thinking beyond it. A social media poll conducted by MedicinMan showed almost predictable responses. 100+ respondents who work in the pharma industry in India were quite clearly divided. 48% of them wanted to know what beyond the pill actually meant, while 23% wanted to know how to execute it. The rest felt that the ultra-competitive environment in the Indian generics market required very high share-of-voice tactics (19%), or that their customers demanded product information (9%).

Any transformational initiative must be driven by the CEO...

Roots Analysis recently published a report on the global Material...

Today's Brand Equity cover — a woman lost in...

Walk into almost any clinic today and you will...

“Lifestyle advice often asks patients to fight powerful evolutionary...

A market analysis and clinical commentary on the growing...

Roots Analysis recently published a report on the global Material...

Today's Brand Equity cover — a woman lost in...

Walk into almost any clinic today and you will...

“Lifestyle advice often asks patients to fight powerful evolutionary...

A market analysis and clinical commentary on the growing...

Roots Analysis recently published a report on the global Material...

Today's Brand Equity cover — a woman lost in...

Walk into almost any clinic today and you will...

“Lifestyle advice often asks patients to fight powerful evolutionary...

A market analysis and clinical commentary on the growing...

Roots Analysis recently published a report on the global Material...

Today's Brand Equity cover — a woman lost in...

Walk into almost any clinic today and you will...

“Lifestyle advice often asks patients to fight powerful evolutionary...

A market analysis and clinical commentary on the growing...